PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...